Literature DB >> 7943779

Prolonged analgesia and decreased toxicity with liposomal morphine in a mouse model.

G J Grant1, K Vermeulen, M I Zakowski, M Stenner, H Turndorf, L Langerman.   

Abstract

Inadequate control of postoperative pain remains a major clinical problem. A reliable method of providing long-lasting postoperative analgesia with a single dose would be very useful. We synthesized a liposomal morphine formulation and compared it to free morphine with regard to duration of analgesia in the mouse. Analgesia was assessed after intraperitoneal injection using the tail-flick test. The systemic toxicity after administration of liposomal and free morphine was compared. The release rate of morphine from liposomes in vitro was also evaluated. The lethal intraperitoneal dose of free morphine in 50% of mice (LD50) was 400 mg/kg. The maximum safe (non-lethal) dose of free morphine was 130 mg/kg. The highest dose of liposomal morphine administered (1650 mg/kg) did not cause death in any animal. Duration of analgesia was significantly prolonged with the highest dose of liposomal morphine (21.5 +/- 5.3 h) compared to the maximum safe dose of free morphine (3.7 +/- 0.75 h), P < 0.01. In vitro experiments showed a slow release rate of morphine from the liposome depot. Prolonged analgesia and decreased systemic toxicity for liposomal morphine are explained by sustained release of morphine from the liposomal depot. These results suggest that liposomal narcotic formulations may provide prolonged analgesia with single-dose administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7943779     DOI: 10.1213/00000539-199410000-00015

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  12 in total

1.  PolyMorphine: an innovative biodegradable polymer drug for extended pain relief.

Authors:  Roselin Rosario-Meléndez; Carolyn L Harris; Roberto Delgado-Rivera; Lei Yu; Kathryn E Uhrich
Journal:  J Control Release       Date:  2012-08-03       Impact factor: 9.776

2.  Future Treatment of Neuropathic Pain in Spinal Cord Injury: The Challenges of Nanomedicine, Supplements or Opportunities?

Authors:  Giuseppe Forte; Valentina Giuffrida; Angelica Scuderi; Mariella Pazzaglia
Journal:  Biomedicines       Date:  2022-06-10

3.  Nanotechnology for Pain Management: Current and Future Therapeutic Interventions.

Authors:  Divya Bhansali; Shavonne L Teng; Caleb S Lee; Brian L Schmidt; Nigel W Bunnett; Kam W Leong
Journal:  Nano Today       Date:  2021-06-19       Impact factor: 18.962

4.  Clinical Management of Pain in Rodents.

Authors:  Patricia L Foley; Lon V Kendall; Patricia V Turner
Journal:  Comp Med       Date:  2019-12-10       Impact factor: 0.982

5.  Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice.

Authors:  L DeTolla; R Sanchez; E Khan; B Tyler; M Guarnieri
Journal:  J Vet Med       Date:  2014-11-27

6.  Subcutaneous implants for long-acting drug therapy in laboratory animals may generate unintended drug reservoirs.

Authors:  Michael Guarnieri; Betty M Tyler; Louis Detolla; Ming Zhao; Barry Kobrin
Journal:  J Pharm Bioallied Sci       Date:  2014-01

7.  Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats.

Authors:  M Guarnieri; C Brayton; R Sarabia-Estrada; B Tyler; P McKnight; L DeTolla
Journal:  J Vet Med       Date:  2017-04-09

8.  A Long-Term Study of a Lipid-Buprenorphine Implant in Rats.

Authors:  Michael Guarnieri; Cory Brayton; Betty M Tyler
Journal:  J Vet Med       Date:  2018-07-09

9.  Liposome-Encapsulated Morphine Affords a Prolonged Analgesia While Facilitating Extinction of Reward and Aversive Memories.

Authors:  Victoria Gómez-Murcia; Bruno Ribeiro Do Couto; Juan C Gómez-Fernández; María V Milanés; María L Laorden; Pilar Almela
Journal:  Front Pharmacol       Date:  2019-09-20       Impact factor: 5.810

10.  PolyMorphine provides extended analgesic-like effects in mice with spared nerve injury.

Authors:  Neil C Lax; Renxun Chen; Sarah R Leep; Kathryn Uhrich; Lei Yu; Benedict Kolber
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.